There are currently 1289 clinical trials in Miami, Florida looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Miami, GSK Investigational Site, University of Miami Miller School of Medicine-Sylvester Cancer Center and University of Miami Miller School of Medicine. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Amnio-Maxx in Patients With Diabetic Foot Ulcers Unresponsive to Standard of Care Treatment Alone
NCT06572839
Recruiting
This randomized controlled study evaluates the adjuvant use of Amnio-Maxx in patients with diabetic foot ulcers
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/28/2025
Locations: Quality Care Clinical Research, Miami, Florida
Conditions: Diabetic Foot Ulcer
Register for Updates
Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) and Diet in Inflammatory Bowel Disease (IBD) Patients
NCT06774079
Recruiting
The purpose of this study is to use diet and an injectable medication called tirzepatide (Zepbound) glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist (GIP-GLP-1 RA) medication as adjunctive therapy (another treatment used together with the primary treatment) for Crohn's disease patients with mild disease who are on stable doses of biologic medication (infliximab or adalimumab) and who have a body mass index (BMI) of at least 27.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/28/2025
Locations: University of Miami, Miami, Florida
Conditions: Crohn Disease
Register for Updates
Minimally Invasive Active Release of Septa Bands for Cellulite and Connective Tissue Release for Fibrosis Treatment in Body Contouring Surgery
NCT06791564
Recruiting
This prospective study aims to evaluate the safety and effectiveness of AVELI for reducing cellulite and fibrotic tissue in patients undergoing High-Definition Liposculpture, exploring if AVELI improves the aesthetic outcomes, and reduced the clinically evident cellulite and/or fibrosis. The main questions this study seeks to answer are: * Does AVELI safely reduce cellulite and fibrotic tissue without causing serious adverse events? * How effective is AVELI in improving patient-reported outcom... Read More
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
04/27/2025
Locations: Miami Aesthetic, Miami, Florida
Conditions: Liposuction, Cellulite, Cellulite Reduction, Fibrosis; Skin
Register for Updates
PromotinG Lung Cancer screenIng Awareness and Implementation in Hispanics/Latinx Head and Neck canceR Survivors
NCT06124508
Recruiting
The purpose of this study is to assess the awareness of eligibility of lung cancer screening in Hispanic/LatinX Head and Neck Cancer (HNC) survivors using a survey questionnaire; and to understand the barriers to screening using qualitative interviews.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
04/25/2025
Locations: University of Miami, Miami, Florida
Conditions: Head and Neck Cancer
Register for Updates
Study of IK-595 in RAS- or RAF-altered Advanced Tumors
NCT06270082
Recruiting
This is a Phase 1, FIH, Dose Escalation and Dose Expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) effects, and preliminary antitumor activity of IK-595, a MEK/RAF molecular glue, administered orally as monotherapy in patients with advanced solid tumors with gene alterations in the RAS- MAPK pathway for whom there are no further treatment options known to confer clinical benefit.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: University of Miami, Miami, Florida
Conditions: Solid Tumor, Adult, Colorectal Cancer, Pancreatic Cancer, Malignant Melanoma, Ras (Kras or Nras) Gene Mutation, BRAF Gene Mutation, CRAF Gene Mutation, Non-Small Cell Lung Carcinoma, Thyroid Carcinoma, Gliomas, Malignant
Register for Updates
Metabolic Impact and Compliance of Controlled, Varying, Mediterranean Diets in Pre-Surgical Prostate Cancer Populations (PROVISIONS)
NCT06487507
Recruiting
The study aims to investigate whether following a controlled Mediterranean-style diet prior to robotic-assisted radical prostatectomy surgery in patients diagnosed with prostate cancer affects fasting insulin levels and other values that can be measured in blood and tissue samples from surgery.
Gender:
MALE
Ages:
Between 18 years and 80 years
Trial Updated:
04/25/2025
Locations: University of Miami, Miami, Florida
Conditions: Prostate Cancer
Register for Updates
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
NCT06767514
Recruiting
Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: Clinical Study Site, Miami, Florida
Conditions: Non-Small Cell Lung Cancer
Register for Updates
An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene
NCT06435000
Recruiting
This is an Observational Study to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene This is a multicenter study which will enroll approximately 75 subjects
Gender:
ALL
Ages:
Between 12 years and 65 years
Trial Updated:
04/24/2025
Locations: Bascom Palmer Eye Institute, Miami, Florida
Conditions: Stargardt, Stargardt's Disease, Stargardt Disease, STGD1
Register for Updates
Auricular Vagus Nerve Stimulation (aVNS) in Chronic Spinal Cord Injuries (SCI)
NCT06588608
Recruiting
The purpose of this research is to test if Auricular Vagal Nerve Stimulation (aVNS) is safe in persons with spinal cord injury (SCI).
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/23/2025
Locations: University of Miami, Miami, Florida
Conditions: Spinal Cord Injuries
Register for Updates
Conditioning SCID Infants Diagnosed Early
NCT03619551
Recruiting
The investigators want to study if lower doses of chemotherapy will help babies with SCID to achieve good immunity with less short and long-term risks of complications after transplantation. This trial identifies babies with types of immune deficiencies that are most likely to succeed with this approach and offers them transplant early in life before they get severe infections or later if their infections are under control. It includes only patients receiving unrelated or mismatched related dono... Read More
Gender:
ALL
Ages:
Between 0 years and 2 years
Trial Updated:
04/22/2025
Locations: University of Miami/Jackson Memorial Hospital, Miami, Florida
Conditions: SCID
Register for Updates
Mitigating the Impact of Stigma and Shame Among MSM Living With HIV and Substance Use Disorders
NCT05934305
Recruiting
Men who have sex with men (MSM), and gender minority individuals who have sex with men, living with HIV and substance use disorders (SUDs) are less likely to be virally suppressed, which can lead to HIV transmission and negative health outcomes. This hybrid type 1 study will assess the efficacy, mechanisms, as well as facilitators and barriers to implementing the MATTER intervention, a virtually delivered 5-session text-enhanced psychobehavioral intervention designed to facilitate viral suppress... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/22/2025
Locations: Florida International University, Miami, Florida
Conditions: Hiv, Substance Use Disorders
Register for Updates
FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)
NCT06402331
Recruiting
This is an open-label, randomized, multicenter study of FPI-2265 (225Ac-PSMA-I\&T). Patient population is adult participants with PSMA positive mCRPC who have had previous treatment with with 177Lu-PSMA-617 or another 177Lu-PSMA radioconjugate (RC). The purpose of the study is to determine the safety and tolerability, and recommended dose and regiment of FPI-2265.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
04/22/2025
Locations: Biogenix Molecular, LLC, Miami, Florida
Conditions: Metastatic Castration-resistant Prostate Cancer
Register for Updates